Scholarlink

Background <p>Multimodal esophageal cancer treatment carries substantial perioperative risks. Although centralization has improved outcomes, variability may persist even among high-volume centers. This study aimed to evaluate inter-institutional heterogeneity in perioperative and survival outcomes using data from JCOG1109.</p> Methods <p>JCOG1109, a phase III multicenter trial, compared neoadjuvant cisplatin plus 5-fluorouracil (CF); docetaxel, cisplatin, and 5-fluorouracil (DCF); and cisplatin and 5-fluorouracil combined with radiotherapy (CF-RT) for stage IB–III esophageal squamous cell carcinoma. Individual patient data and institutional survey results were analyzed. Mixed-effects models with random intercepts and slopes, incorporating institutions as random effects, were applied to quantify heterogeneity in DCF and CF-RT’s treatment effects on postoperative complications, progression-free survival (PFS), and overall survival (OS), separated from baseline institutional risks in the CF arm.</p> Results <p>From 44 institutions, 580 patients were eligible and 546 underwent surgery. PFS treatment effect variance was smaller than baseline risk variability (CF: 0.062, standard deviation [SD]: 0.069; DCF: 0.044, SD: 0.053; CF-RT: 0.051, SD: 0.057), whereas OS variance exceeded baseline risk (CF: 0.058, SD: 0.068; DCF: 0.080, SD: 0.094; CF-RT: 0.072, SD: 0.079). Complication variance was lower in both experimental arms (CF: 0.342, SD: 0.432; DCF: 0.111, SD: 0.168; CF-RT: 0.190, SD: 0.326), although it was greater in the CF-RT arm than in the DCF arm.</p> Conclusions <p>Multimodal treatment was delivered with high consistency across specialized centers, as reflected by minimal heterogeneity in PFS. In contrast, moderate heterogeneity in OS indicated institutional influences, particularly post-recurrence management, which should be considered in trial designs and clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A)

  • 期刊论文

  • 发表日期：

    2026年6月30日

查看全文
  • Ryosuke Kita,
  • Ryunosuke Machida,
  • Haruhiko Fukuda,
  • Ken Kato,
  • Yoshinori Ito,
  • Hiroyuki Daiko,
  • Koshiro Ishiyama,
  • Hiroki Hara,
  • Masato Nishida,
  • Kazuo Koyanagi,
  • Tetsuya Abe,
  • Takeo Fujita,
  • Takeo Bamba,
  • Takahiro Tsushima,
  • Keita Sasaki,
  • Shigeru Tsunoda,
  • Koya Hida,
  • Kazutaka Obama,
  • Hiroya Takeuchi

摘要

Background

Multimodal esophageal cancer treatment carries substantial perioperative risks. Although centralization has improved outcomes, variability may persist even among high-volume centers. This study aimed to evaluate inter-institutional heterogeneity in perioperative and survival outcomes using data from JCOG1109.

Methods

JCOG1109, a phase III multicenter trial, compared neoadjuvant cisplatin plus 5-fluorouracil (CF); docetaxel, cisplatin, and 5-fluorouracil (DCF); and cisplatin and 5-fluorouracil combined with radiotherapy (CF-RT) for stage IB–III esophageal squamous cell carcinoma. Individual patient data and institutional survey results were analyzed. Mixed-effects models with random intercepts and slopes, incorporating institutions as random effects, were applied to quantify heterogeneity in DCF and CF-RT’s treatment effects on postoperative complications, progression-free survival (PFS), and overall survival (OS), separated from baseline institutional risks in the CF arm.

Results

From 44 institutions, 580 patients were eligible and 546 underwent surgery. PFS treatment effect variance was smaller than baseline risk variability (CF: 0.062, standard deviation [SD]: 0.069; DCF: 0.044, SD: 0.053; CF-RT: 0.051, SD: 0.057), whereas OS variance exceeded baseline risk (CF: 0.058, SD: 0.068; DCF: 0.080, SD: 0.094; CF-RT: 0.072, SD: 0.079). Complication variance was lower in both experimental arms (CF: 0.342, SD: 0.432; DCF: 0.111, SD: 0.168; CF-RT: 0.190, SD: 0.326), although it was greater in the CF-RT arm than in the DCF arm.

Conclusions

Multimodal treatment was delivered with high consistency across specialized centers, as reflected by minimal heterogeneity in PFS. In contrast, moderate heterogeneity in OS indicated institutional influences, particularly post-recurrence management, which should be considered in trial designs and clinical practice.